Patents by Inventor Kevin T. Mellem

Kevin T. Mellem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240101577
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 17, 2023
    Publication date: March 28, 2024
    Inventors: Elena S. KOLTUN, Naing N. AAY, Andreas BUCKL, Kevin T. MELLEM, Brian R. BLANK, Jennifer PITZEN, Gang WANG, Ashutosh S. JOGALEKAR, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Adrian Liam GILL, James Joseph CREGG
  • TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS
    Publication number: 20240018105
    Abstract: Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia or Ib and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia or Ib compounds or tautomers or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 16, 2020
    Publication date: January 18, 2024
    Applicant: Kinesid Therapeutics, Inc.
    Inventors: Jianhua Chao, Stanley J. Hollenbach, Michael C. Holmes, Douglas M. Matje, Nicholas M. Snead, Gustave Bergnes, Kevin T. Mellem, David J. Morgans, Jr, Walter S. Won
  • Polycyclic compounds as allosteric SHP2 inhibitors
    Patent number: 11673901
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: June 13, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
  • Polycyclic compounds as allosteric SHP2 inhibitors
    Patent number: 11634435
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: April 25, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20230055672
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20210338824
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 28, 2020
    Publication date: November 4, 2021
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
    Patent number: 10980889
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: April 20, 2021
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • Derivatives of amphotericin B
    Patent number: 10882883
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: January 5, 2021
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20200407372
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: June 11, 2020
    Publication date: December 31, 2020
    Inventors: Elena S. KOLTUN, Naing N. AAY, Andreas BUCKL, Kevin T. MELLEM, Brian R. BLANK, Jennifer PITZEN, Gang WANG, Ashutosh S. JOGALEKAR, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Adrian Liam GILL, James Joseph CREGG
  • DERIVATIVES OF AMPHOTERICIN B
    Publication number: 20200262858
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 20, 2020
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of amphotericin B
    Patent number: 10597420
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 24, 2020
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20190336609
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2019
    Publication date: November 7, 2019
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • DERIVATIVES OF AMPHOTERICIN B
    Publication number: 20180273572
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Application
    Filed: April 9, 2018
    Publication date: September 27, 2018
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of amphotericin B
    Patent number: 9957290
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 1, 2018
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of Amphotericin B
    Publication number: 20160304548
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney